CIBC Private Wealth Group
CTIC

CIBC Private Wealth Group’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

CIBC Private Wealth Group’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-50
Closed – – 2004
2018
Q2 		$0 Hold
50
– – ﹤0.01% 2192
2018
Q1 		$0 Hold
50
– – ﹤0.01% 2189
2017
Q4 		$0 Buy
+50
New +$147 ﹤0.01% 2031

Other funds holding CTIC

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CIBC Private Wealth Group's CTIC Position: Q3 2018 in Review

CIBC Private Wealth Group sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q3 2018, closing a stake of 50 shares.

CIBC Private Wealth Group first reported a position in CTIC in Q4 2017 and held it in 3 quarters. The position peaked at $0 in Q2 2018. 79 funds tracked by Wall St. Rank hold CTIC as of Q3 2018.

  • CIBC Private Wealth Group reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q3 2018 after selling out during the quarter.
  • CIBC Private Wealth Group sold 50 CTI BioPharma Corp. (DE) Common Stock shares in Q3 2018.
  • CIBC Private Wealth Group first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2017 and held it in 3 quarters.
  • CIBC Private Wealth Group's CTI BioPharma Corp. (DE) Common Stock position peaked at $0 in Q2 2018.
  • 79 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q3 2018.

Based on CIBC Private Wealth Group's 13F filing for Q3 2018, filed 14 Nov 2018.